Venus Receives Market Authorization for Meropenem from Switzerland

Venus Receives Market Authorization for Meropenem from Switzerland

Venus Remedies Limited, a leading research based global pharmaceutical company, achieved yet another landmark by receiving marketing authorization in Switzerland through its German subsidary Venus Pharma GmbH from Swiss drug authority (SWISSMEDIC) for its generic product Meropenem 500 mg & 1 g Injection. Meropenem is a carbapenem drug of last resort being used in ICU. This market approval of critically important antibiotic drug will help Venus to strengthen its portfolio in Swiss market. The company is planning to launch this product early next year through its partner Swiss Pharma GmbH Zurich, to expand its presence in the division.

Source: Venus Remedies (Link to full release)

About the author

Amitabh Arora

Amitabh Arora

Amitabh Arora has more than 18 years of experience promoting foreign direct investments (FDI), trade and economic relations between India and Switzerland, South Korea, United Kingdom and Canada. He is currently working as Director Key Accounts at the Greater Geneva Berne area (GGBa), the economic development agency of western Switzerland. GGBa offers a comprehensive range of services at no charge to foreign companies seeking to establish a presence in Switzerland. He is also the founder of FDITracker.com, tracking FDI developments worldwide. Amitabh has a Masters in International Business from the Indian Institute of Foreign Trade (IIFT) and a Bachelor of Business Studies (BBS) from College of Business Studies, India.

    Leave a Reply